当前位置: 首页 > 期刊 > 《中国实用医药》 > 2012年第23期 > 正文
编号:12273458
香菇多糖对原发性肝癌TACE前后外周血CD4+CD25+调节性T细胞的影响(1)
http://www.100md.com 2012年8月15日 姚庆兰
第1页

    参见附件。

     【摘要】目的观察香菇多糖在原发性肝癌(TACE)前后对外周血CD4+CD25+调节性T细胞的变化,探讨香菇多糖对原发性肝癌患者的免疫调节机制。方法原发性肝癌46例,随机分为治疗组24例,对照组22例,治疗组在TACE术后第1天给予香菇多糖1 mg,3次/周,两组化疗方案相同,在TACE前及TACE后4周分别抽外周血, 应用流式细胞术检测CD4+CD25+调节性T细胞的变化。结果外周血CD4+CD25+Treg细胞占CD4+T细胞的百分率:治疗组在TACE前为(1059±434)%、TACE后4周(672±260)%;对照组在TACE术前为(1021±442)%、TACE后4周为(856±312)%。在TACE前两组间差异无统计学意义(P>005);TACE后4周时治疗组较对照组低,两组间差异有统计学意义(P<005)。结论香菇多糖可提高恶性肿瘤患者的免疫功能,在TACE后立即给药效果更佳。

    【关键词】香菇多糖;原发性肝癌;TACE术; 流式细胞术;CD4+CD25+调节性T细胞

    Lentinan peripheral blood CD4+CD25+regulatory T cells before and after TACE of primary liver cancerYAO Qinglan Division of the Fourth Peoples Hospital of Huaian City, Jiangsu Province, liver disease,Huai’an 223000,China

    【Abstract】ObjectiveObserved lentinan in primary liver cancer (TACE) before and after changes in peripheral blood CD4+CD25+regulatory T cells,Explore the immunomodulatory mechanisms of lentinan on patients with primary liver cancer. Methods46 cases of primary liver cancer were randomly divided into treatment group 24 cases, 22 cases in the control group,Treatment group in the first day after TACE, lentinan 1 mg, 3 times / week, two groups of the same chemotherapy regimenTACE before and after TACE four weeks were drawn peripheral blood, detected by flow cytometry of CD4+CD25+regulatory T cells changes ResultsPeripheral blood of CD4+CD25+Treg cells accounted for the percentage of CD4+ T cells: treatment group (1059±434)% before the TACE, the TACE after four weeks (672±260)%; control group with TACE before (1021±442)% 4 weeks after the TACE (856±312)% No significant difference between the two groups before the TACE (P> 005); four weeks after the TACE treatment group than the control group, there was significant difference between the two groups (P<005) ConclusionLentinan can improve the immune function of patients with malignant tumors, immediately after TACE administration better ......

您现在查看是摘要介绍页,详见PDF附件(2744kb)